Bristol-Myers Squibb Company (BMY) Release: First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress  
5/28/2009 1:18:23 PM

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of nine company-sponsored clinical presentations at the upcoming American Transplant Congress to be held May 30 to June 3 in Boston. Belatacept is in phase III development.